The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins

Blood

Volumn 98, Issue 13, 2001, Pages 3778-3783

  Demiroglu, Asuman ^a,b,c,d,e   Joanna Steer, E ^a,b,c,d,e   Heath, Carol ^a,b,c,d,e   Taylor, Kerry ^a,b,c,d,e   Bentley, Mark ^a,b,c,d,e   Allen, Steven L ^a,b,c,d,e   Koduru, Prasad ^a,b,c,d,e   Brody, Judith P ^a,b,c,d,e   Hawson, Geoffrey ^a,b,c,d,e   Rodwell, Robyn ^a,b,c,d,e   Doody, Mary Lou ^a,b,c,d,e   Carnicero, Fernando ^a,b,c,d,e   Reiter, Andreas ^a,b,c,d,e   Goldman, John M ^a,b,c,d,e   Melo, Junia V ^a,b,c,d,e   Cross, Nicholas C P ^a,b,c,d,e,f  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b MATER ADULT HOSPITAL   (Australia)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d NAMBOUR GENERAL HOSPITAL   (Australia)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BCR ABL PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; INTERLEUKIN 3; MESSENGER RNA; PROTEIN INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CASE REPORT; CELL GROWTH; CELL TRANSFORMATION; CHROMOSOME 22; CHROMOSOME 8; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DISRUPTION; GENE FUSION; GENE IDENTIFICATION; HUMAN; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0035895067     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3778     Document Type: Article

References (33)

1. Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol. 1997;10:203-222.
2. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosomenegative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood. 1990;75:445-452.
3. Shepherd PC, Ganesan TS, Galton DA. Haematological classification of the chronic myeloid leukaemias. Baillieres Clin Haematol. 1987;1:887-906.
4. Oscier DG. Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome? Br J Haematol. 1996;92:582-586.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
6. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
7. Smedley D, Hamoudi R, Clark J, et al. The t(8; 13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet. 1998;7:637-642.
8. Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci U S A. 1998;95:5712-5717.
9. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 1998;92:1735-1742.
10. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18:84-87.
11. Popovici C, Zhang B, Gregoire MJ, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood. 1999;93:1381-1389.
12. Kulkarni S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 2000;60:3592-3598.
13. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood. 2000;95:1788-1796.
14. Sohal J, Chase A, Mould S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer. 2001;32:155-163.
15. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8:186-189.
16. Smedley D, Demiroglu A, Abdul-Rauf M, et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATs 1 and 5. Neoplasia. 1999;1:349-355.
17. Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NCP. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia. 1995;9:1628-1630.
18. McWhirter JR, Galasso DL, Wang JY. A coiledcoil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587-7595.
19. Xiao S, McCarthy JG, Aster JC, Fletcher JA. ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. Blood. 2000;96:699-704.
20. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
21. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997;276:955-960.
22. Hara M, Akasaka K, Akinaga S, et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci U S A. 1993;90:2281-2285.
23. Mahgoub N, Taylor BR, Gratiot M, et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 1999;94:2469-2476.
24. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997;96:111-116.
25. Inhorn RC, Aster JC, Roach SA, et al. Asyndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995;85:1881-1887.
26. Mugneret F, Chaffanet M, Maynadie M, et al. The 8p12 myeloproliferative disorder t(8;19)(p12; q13.3): a novel translocation involving the FGFR1 gene. Br J Haematol. 2000;111:647-649.
27. Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 2000;96:664-670.
28. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 1991;67:459-468.
29. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;181:307-313.
30. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1401-1412.
31. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
32. Reddy KS, Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genet Cytogenet. 2000;118:121-131.
33. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.